Entering text into the input field will update the search result below

WHO backs Merck/Ridgeback's pill molnupiravir for certain COVID-19 patients

Mar. 03, 2022 5:07 AM ETMerck & Co., Inc. (MRK)By: Ravikash, SA News Editor

COVID-19 experimental antiviral drug MOLNUPIRAVIR

Plyushkin/iStock via Getty Images

  • The World Health Organization in its updated guidelines have included conditional recommendation for Merck & Co. (NYSE:MRK) and Ridgeback Biotherapeutics' COVID-19 pill molnupiravir.
  • The WHO said it the first oral antiviral drug to be included in the treatment

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.